Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EBITDA: 2015-2025

Historic EBITDA for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to -$24.5 million.

  • Editas Medicine's EBITDA rose 62.62% to -$24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$198.8 million, marking a year-over-year increase of 12.99%. This contributed to the annual value of -$251.2 million for FY2024, which is 48.45% down from last year.
  • Editas Medicine's EBITDA amounted to -$24.5 million in Q3 2025, which was up 52.37% from -$51.5 million recorded in Q2 2025.
  • Editas Medicine's EBITDA's 5-year high stood at -$24.0 million during Q4 2023, with a 5-year trough of -$76.2 million in Q1 2025.
  • Moreover, its 3-year median value for EBITDA was -$51.0 million (2023), whereas its average is -$52.1 million.
  • In the last 5 years, Editas Medicine's EBITDA slumped by 536.68% in 2021 and then surged by 62.62% in 2025.
  • Quarterly analysis of 5 years shows Editas Medicine's EBITDA stood at -$41.6 million in 2021, then tumbled by 52.48% to -$63.4 million in 2022, then soared by 62.23% to -$24.0 million in 2023, then tumbled by 94.45% to -$46.6 million in 2024, then spiked by 62.62% to -$24.5 million in 2025.
  • Its EBITDA stands at -$24.5 million for Q3 2025, versus -$51.5 million for Q2 2025 and -$76.2 million for Q1 2025.